Zai Lab Ltd(ZLAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,280 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
ZLAB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Zai Lab Ltd (ZLAB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZLAB at 36.1/100 on a 32-signal composite quality model, placing it at rank #2,280 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Zai Lab Ltd reports quarterly revenue of $106.3M, net income of $-50.8M, free cash flow of $-64.7M. Top institutional holders of ZLAB by reported 13-F value include RTW INVESTMENTS, TCG Crossover Management, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. ZLAB trades on the Nasdaq exchange and files with the SEC under CIK 1704292. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZLAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zai Lab Ltd directly from SEC EDGAR. Zai Lab Ltd's 13F Pro composite quality score has ranged between 30 and 36 since 2026, currently 36.1 — an improving long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue
Q2 2026
$106.3M
Net Income
Q2 2026
$-50.8M
Free Cash Flow
Q2 2026
$-64.7M
ROIC
Q2 2026
-36.2%
D/E Ratio
Q2 2026
0.39
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+15.3% YoYNet Income
+31.7% YoYOperating Income
+18.7% YoYEPS (Diluted)
+38.5% YoYTotal Assets
-1.1% YoYTotal Debt
+55.3% YoYOp. Cash Flow
+29.8% YoYFree Cash Flow
+27.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $460.2M +15.3% | $399.0M +49.6% | $266.7M +24.0% | $215.0M +49.0% | $144.3M +194.8% | $49.0M |
| Net Income | $-175.5M +31.7% | $-257.1M +23.2% | $-334.6M +24.5% | $-443.3M +37.1% | $-704.5M -162.0% | $-268.9M |
| Operating Income | $-229.4M +18.7% | $-282.1M +23.0% | $-366.6M +9.3% | $-404.4M +42.2% | $-700.1M -132.0% | $-301.8M |
| EPS (Diluted) | $-0.16 +38.5% | $-0.26 +25.7% | $-0.35 +23.9% | $-0.46 -505.3% | $-0.08 -117.1% | $-0.04 |
| Total Assets | $1.17B -1.1% | $1.19B +14.4% | $1.04B -15.1% | $1.22B -24.2% | $1.61B +24.1% | $1.30B |
| Total Debt | $204.5M +55.3% | $131.7M | $0.00 | — | — | — |
| Operating Cash Flow | $-150.8M +29.8% | $-214.9M -8.4% | $-198.2M +46.1% | $-367.6M +33.1% | $-549.2M -154.2% | $-216.1M |
| Free Cash Flow | $-158.9M +27.9% | $-220.5M -7.4% | $-205.4M +47.6% | $-392.2M +30.9% | $-567.5M -150.9% | $-226.2M |
Get alerted when ZLAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Zai Lab Ltd including:
Top Institutional Holders of ZLAB
RTW INVESTMENTS, LP
$124.9M6,574,032 shTCG Crossover Management, LLC
$116.6M6,137,627 shRA CAPITAL MANAGEMENT, L.P.
$109.1M5,743,533 shADAR1 Capital Management, LLC
$64.0M3,369,034 shFMR LLC
$53.5M2,815,214 shGOLDMAN SACHS GROUP INC
$44.0M2,315,480 shWoodline Partners LP
$41.9M2,207,293 shFrazier Life Sciences Management, L.P.
$36.1M1,902,320 shBAMCO INC /NY/
$30.9M1,623,694 shTWO SIGMA INVESTMENTS, LP
$24.7M1,299,394 sh
| Fund | Value | Shares |
|---|---|---|
| RTW INVESTMENTS, LP | $124.9M | 6,574,032 |
| TCG Crossover Management, LLC | $116.6M | 6,137,627 |
| RA CAPITAL MANAGEMENT, L.P. | $109.1M | 5,743,533 |
| ADAR1 Capital Management, LLC | $64.0M | 3,369,034 |
| FMR LLC | $53.5M | 2,815,214 |
| GOLDMAN SACHS GROUP INC | $44.0M | 2,315,480 |
| Woodline Partners LP | $41.9M | 2,207,293 |
| Frazier Life Sciences Management, L.P. | $36.1M | 1,902,320 |
| BAMCO INC /NY/ | $30.9M | 1,623,694 |
| TWO SIGMA INVESTMENTS, LP | $24.7M | 1,299,394 |
Companies Similar to ZLAB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Relay Therapeutics, Inc.
Century Therapeutics, Inc.
Ultragenyx Pharmaceutical Inc.
Editas Medicine, Inc.
Xencor Inc
Altimmune, Inc.
Evolus, Inc.
Verastem, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ZLAB on your watchlist
Track score changes the day Zai Lab Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ZLAB a good stock to buy?
13F Pro's AI-powered analysis of Zai Lab Ltd (ZLAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZLAB are available on the ZLAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZLAB is classified as a mid company.
Which hedge funds own ZLAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZLAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zai Lab Ltd's investment landscape.